1991

FDA’s Antiviral Advisory Committee endorses use of CD4 counts (T-cell counts) as surrogate marker for demonstrating efficacy of nucleotide analogues in treatment of AIDS. In July, Committee recommended licensing of DDL, and in 1992, it gave “conditional approval” to DDC when used in conjunction with AZT (Epstein, 276-280).